Piramal Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 30, 2025
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Piramal Pharma has informed the exchanges about its 5th Annual General Meeting (AGM) scheduled for Wednesday, July 30, 2025 at 3:00 p.m. IST, to be held via video conferencing. The company submitted its Annual Report for FY2024-25 along with the AGM notice, pursuant to SEBI Listing Regulations. The report highlights a strong year with revenue from operations of ₹9,151 crore (up 12% YoY), crossing the US$ 1 Billion milestone, and EBITDA of ₹1,580 crore at a 17% margin. Net profit turned around to ₹91 crore from a loss of ₹186 crore in FY23. The CDMO business led growth at 15%, while CHG and Consumer Healthcare grew 8% and delivered steady double-digit growth respectively. Net debt-to-EBITDA improved to 2.7x from 5.6x in FY23.
This is a routine regulatory filing for the AGM and annual report, with no direct stock price trigger. However, the embedded FY25 results show solid revenue growth, margin expansion, and a major turnaround in net profit, which are positive indicators for shareholders. Investors should review the detailed annual report for segment-level insights ahead of the AGM on July 30, 2025.